Scancell (LON:SCLP) Shares Up 20.2% - What's Next?

Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) rose 20.2% during trading on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.19 ($0.14). Approximately 1,738,488 shares changed hands during mid-day trading, an increase of 124% from the average daily volume of 777,450 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The firm has a market capitalization of £109.27 million, a price-to-earnings ratio of -16.18 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The business has a 50-day moving average price of GBX 8.58 and a two-hundred day moving average price of GBX 10.80.

Scancell (LON:SCLP - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. As a group, research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.